Why Delic Corp is the Best Bet in This Emerging Market
September 9, 2021
Delic Corp (OTCQB: DELCF / CSE: DELC) is one of those rare investment opportunities that we would call a “no-brainer”. With strong financial trends, experienced leadership, a growing market, and a truly innovative approach, we think it’s a good time to jump onboard Delic’s rocketship.
So what exactly is Delic Corp? It’s a psychedelic wellness company, focusing on fully legal opportunities (like its recent ketamine clinic acquisition) in the psychedelic space. Delic’s M&A strategy leans on the leadership’s connections and experience from over 25 years in the cannabis industry to evaluate and execute on opportunities in the red-hot psychedelic space.
Delic is the leading psychedelic wellness platform, committed to bringing safe, legal and science-backed benefits and treatment to the masses and reframing the psychedelic conversation.
They are (building) the largest and most accessible chain of psychedelic wellness clinics in the country and a scalable ecosystem to increase revenue, margins and patient base. As future psychedelic treatments are legalized we will offer additional options across the largest provider network, no matter where you’re located in America, with a keen focus on serving 2nd cities and the bulk of the population.
They’re focused on bringing psychedelic wellness to the mainstream through an umbrella of related businesses we own and operate to support scaling the impact and reach of treatment, including 1) trusted media and e-commerce platforms and in-person events to market the services directly to patients and consumers and gain data, 2) a licensed lab to develop IP, R&D and innovative high quality and safe product lines and 3) the largest and most accessible network of physical clinics to administer effective treatments.
In short, they have built a direct pipeline to consumers and patients, scaled it across platforms both online and offline and are putting more people into our clinics across the country.
We all know the explosion of the cannabis industry led to massive returns for early investors, and it’s clear that those kinds of returns can be replicated with psychedelics. Now it’s only a matter of choosing the right horse, and we think that Delic is a front runner.
Market Potential – Let’s be blunt; we’re talking about several, multi-billion markets here.
Delic is at the cross-section of the $500B US prescription drug market, the $238B US mental health/depression market, and the psychedelic treatment market, projected to reach $10.7B by 2027.
As the efficacy of psychedelic compounds continues to be studied, the prescription drug and mental health markets will be radically disrupted. To what extent only depends on how quickly certain compounds will be legalized, and based on the ketamine case study, that won’t be too long. Delic is poised to disrupt billion dollar markets, and grow exponentially with the acquisition of successful companies in the space.
Strategy – The pharma angle is a popular one with things like psychedelics. But Delic is taking a different (dare we say better) approach; they are focused on fully legal opportunities to take psychedelics mainstream. Rather than having to wait around for drug trials, changing legislation, and other roadblocks, Delic is using an M&A model to create massive growth within the industry RIGHT NOW. It is a unique strategy that we think will put Delic ahead of competitors who have to deal with multiple layers of red tape.
Shifting Attitudes – Ask almost anyone born before the 60s and you’ll find resistance to the idea that psychedelics can be used therapeutically. Luckily, that is changing. A preponderance of evidence is beginning to show that certain psychedelic compounds treat depression, anxiety, and other mental health disorders faster and more effectively than current medications. Ketamine has been approved by the FDA as a fast-acting treatment for depression, while LSD & psilocybin have been shown to reduce end-of-life anxiety in 80% of terminally ill patients. The tide is clearly shifting in favor of these treatments, and with 50% of the population suffering from some kind of mental health disorder, attitudes toward fast-acting and non-addictive treatments is at an all time high.
Learning From History – Not too long ago we saw cannabis companies go vertical, with some investors seeing 4-figure stock gains. And you know what they say about people who don’t learn from history? The pattern is repeating; a formerly illegal substance is gaining popularity, several companies are beginning to build foundations for growth, and it’s only a matter of time before some kind of medical legalization sweeps across the majority of North America. We’ve already seen several psychedelic companies spike in value (Mind Medicine and Revive Therapeutics both experienced over 2,000% growth in 2020), so it’s clear that psychedelics are the next cannabis. Delic is perfectly positioned for that kind of growth as they continue to acquire proven winners.
A Unique Approach to Wellness
Delic Corp is the leading psychedelic wellness platform, committed to bringing science-backed benefits to everyone, while reframing the conversation around psychedelics. It owns and operates an umbrella of related entities, acquiring and scaling fully legal businesses already operating in the space. We believe this approach to be an intelligent direction for Delic, as many competitors will be wasting time trying to get products approved by the FDA or other governing bodies, while Delic is already generating cash flow.
Delic owns media and e-commerce platforms like Reality Sandwich and DELIC Radio, which are building a grassroots audience of potential consumers while positioning the Company as a trusted source of information.It also hosts Meet Delic; the premiere psychedelic wellness event, where thought leaders and scientists speak to the future of psychedelic wellness.
The Reality Sandwich website boasts over 5000 pieces of free content, 460k website users in 2020, 1.4M website pageviews in 2020, and favorable Google keyword rankings. Reality Sandwich also has 54k followers across all platforms and an email list almost 7k strong. Ownership over the digital space is crucial for growing companies, as it can help create trust, leading to more predictable buying patterns and better direct sales opportunities.
To further its reach and help bring psychedelics to the mainstream, Delic hosts Meet Delic – the world’s premier psychedelic and wellness edutainment event. Last year’s online stream attracted thousands of live viewers and thousands more replay downloads. This year’s conference will be held in AREA15, an immersive and experiential entertainment complex in the heart of Las Vegas. The two-day event features industry entrepreneurs, psychonauts, and leading voices in research, science, and wellness. This event positions Delic as an industry leader, creating even more trust and esteem among consumers and potential partners.
Psychedelic Radio is Delic’s podcast, covering all things psychedelic-related. Since 2018 it has garnered more than 100k streams.
Finally, Delic has had no trouble getting featured in publications outside their owned media platforms.
In Delic’s case, the proliferation of media exposure is highly important. Not only does it lend credibility to the company as a leader in an emerging market, each mention of Delic and its mission enhances the public’s view on psychedelic wellness as a whole.
A huge part of cannabis’ growth came from its pervasiveness throughout culture and publications. Matt Stang knows from experience how important optics are from his time as owner and operator of High Times. The magazine played a massive role in helping educate consumers on the industry, providing a cultural touchstone for emerging products, and giving legitimacy to what was once frowned upon.
We see Reality Sandwich, along with Delic’s other platforms, as key growth drivers for future e-commerce efforts, as well as an innovative way to disseminate pertinent information about psychedelic wellness. With Matt Stang at the helm, it seems likely this area will thrive.
Delic has recently acquired Ketamine Infusion Centers (KIC), one of the largest ketamine clinics in the country. This move is just the beginning of Delic’s M&A strategy, geared toward acquiring legal opportunities that are proven to help people, and scaling them to build value.
From a recent press release, “Today’s closing ensures we can execute on our growth strategy of leveraging DELIC’s media properties to drive patient acquisition,” Sonny Diaz, Co-Founder of KIC stated. “This closed ecosystem of media properties, a lab to produce high-quality and innovative products, and a national chain of health clinics at the center is a game changer for scaling psychedelic wellness. KIC’s history of profitability and our management team with decades of experience in the health sector and successful exits of over two dozen clinics and hospitals will enable DELIC to be the national leader in legal psychedelic treatment.
KIC has expanded from Arizona to California in the last three years, delivered 4,000 treatments, and generated over $1.5M in revenue. The average cost to open a ketamine treatment clinic is $250k, and can generate $1M of revenue at a 25%-30% operating profit. DELIC plans to open 10 such clinics over the next 18 months, building on the success of what KIC has done so far.
Delic has the unique ability to drive customers to brick and mortar treatment centers vis-a-vis their digital media holdings. A winning strategy indeed. Going forward, KIC will operate under the DELIC umbrella, under the direction and guidance of Dr. Christopher Ray, Sonny Diaz, Rogelio Monzon, and Ganesh Acharya.
While nothing has been announced, we wouldn’t be surprised to see Delic acquire more health-focused ventures before the year is out.
Delic Labs (formerly Complex Biotech Discovery Ventures Ltd.) is the only licensed entity by Health Canada to exclusively focus on research and development of psilocybin vaporization technology.
Delic Labs serves as the engine for the Delic platform, conducting research and developing innovative product lines and intellectual property (IP) future distribution across it’s physical footprint and licensed psychedelic wellness clinics in the United States.
From a recent press release, “We are thrilled to be an integral part of the Delic platform and provide high-quality research and products to an ever-growing number of patients.” said Dr. Markus Roggen, Delic Labs’ President and CSO. “The resources and connections the Delic team brings to our network will help ensure long-term success in psychedelic innovation and technology throughout the world.”
Founded by award-winning chemists, Delic Labs focuses on extraction optimization, analytical testing, and chemical process development to advance the cannabis and psilocybin industries. It was granted a Section 56 exemption from Health Canada to commence their work with psilocybin compounds, allowing the company to possess and research these products for development and quality control before they hit the market.
The lab is pursuing development of psilocybin analogs that could be used in future medical treatments, while new projects like “Advanced Analytical Service” and “The Compound Database” will bring in scalable revenue streams.
Current and past customers of the lab are well-established global enterprises who require cutting-edge cannabis and soon, psilocybin research. Founded by award-winning chemist, Dr. Markus Roggen, and UBC Professor, Dr. Glenn Sammis, Delic Labs supports the psychedelic industry with high precision chemical analytics, metabolomic identification and process optimization. It has an aggressive plan to build out a suite of novel compounds and delivery methods for the industry, and is applying for a Dealer’s License with the intent to eventually commercialize its psilocybin research and associated intellectual property (IP).
Being the only lab licenced to research psilocybin in Canada is a massive advantage for Delic. The continued efforts of the lab, combined with the marketing engine that is Delic’s media arm makes for a powerful combo. For each new product, Delic will be able to directly target a curated audience eager to experience the newest things in psychedelic wellness. This is a powerful strategy that we’re betting works every time.
The PsycheDELIC Revolution
Backed by a team of industry and cannabis veterans and a diverse network with a mission to provide education, research, high-quality products, and treatment options to the masses, Delic is undoubtedly at the forefront of the psychedelic wellness revolution.
In its favor is a carefully cultivated audience being primed to experience services and products brought to them by Delic’s umbrella of businesses. The pipeline has been built, now we just have to see how quickly it can be scaled.
Also worth mentioning is the power of Delic’s Board of Directors. Sitting behind Delic is a deep pool of experience that includes CEO’s/Founders of PharmaCann, MagicalButter, Apollo Neurosciences, and more. Delic is being guided by people who have taken companies to BILLION dollar valuations, and that’s nothing to sneeze at.
Delic has a reasonably tight share structure, focusing on raising just enough capital to acquire ventures and create actual value for shareholders. This shows extreme confidence in their strategy, and so far it seems to be working.
We think that, just like cannabis did so recently, the psychedelic space is about to explode, and Delic has all the right stuff to go along for the ride.
Who are we and what do we do?
We are paid advertisers, also known as stock touts or stock promoters, who disseminate favorable information (the “Information”) about publicly traded companies (the “Profiled Issuers”).
How is the Information published?
We publish the Information on our Website, in newsletters, audio services, live interviews, featured “research” reports, on message boards and in email communications for specific time periods that are agreed upon between us and the Profiled Issuer or third party paying us.
Our publication of the Information is known as a “Campaign”.
Will everyone receive the Information at the same time?
No. The Information may be sent to potential investors at different times that are minutes, hours, days or even weeks apart.
How is a potential investor impacted if he receives the Information later than other investors?
Typically, the trading volume and price of a Profiled Issuer’s securities increases after the Information is provided to the first group of investors. Therefore, the later an investor receives the Information, the more likely it is that he will suffer increased trading losses if he purchases the securities of a Profiled Issuer.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase during the Campaign.
What will happen when the Campaign ends?
Most, if not all, of the Profiled Issuers are penny stocks that are illiquid and whose securities are subject to wide fluctuations in trading price and volume. During the Campaign the trading volume and price of the securities of each Profiled Issuer will likely increase significantly. When the Campaign ends, the volume and price of the Profiled Issuer will likely decrease dramatically. As a result, investors who purchase during the Campaign and hold shares of the Profiled Issuer when the Campaign ends will probably lose most, if not all, of their investment.
Why do we publish only favorable Information?
We only publish favorable information because we are compensated to publish only favorable information.
Why don’t we publish negative Information?
We don’t publish negative information because we are not paid to publish negative information. We are paid to publish only favorable information.
Is the Information complete, accurate, truthful or reliable?
No. The Information is a snapshot that provides only positive information about the Profiled Issuers. The Information consists of only positive content. We do not and will not publish any negative information about the Profiled Issuers; accordingly, investors should consider the Information to be one-sided and not balanced, complete, accurate, truthful or reliable.
What we do not do?
We do not publish negative information about the Profiled Issuers. We do not verify or confirm any portion of the Information. We do not conduct any due diligence, nor do we research any aspect of the Information including the completeness, accuracy, truthfulness or reliability of the Information. We do not review the Profiled Issuers’ financial condition, operations, business model, management or risks involved in the Profiled Issuer’s business or an investment in a Profiled Issuer’s securities.
Where does the Information come from?
The Information is provided to us by the Profiled Issuers and/or the person who hires us. We may also obtain the Information from publicly available sources such as the OTC Markets, Google, NASDAQ, NYSE, the Securities and Exchange Commission’s Edgar database or other available public sources.
If we say we make “stock picks,” are those picks our own?
No, they are not. We are compensated to advertise the securities we are told to advertise.
What will happen if an investor relies on the Information?
If an investor relies on the Information in making an investment decision it is highly probable that the investor will lose most, if not all, of his or her investment. Investors should not rely on the Information to make an investment decision.
Who pays us to publish the Information?
The source of our compensation varies depending upon the particular circumstances of the Campaign. We are compensated by the Profiled Issuers, third party shareholders and other parties related to the Profiled Issuers such as officers and/or directors who will derive a financial or other benefit from an increase in the trading price and/or volume of a Profiled Issuer’s securities.
The nature and amount of compensation we receive for publishing the Information about each Profiled Issuer and our ownership of each Profiled Issuer is set forth below under the heading captioned, “What we are compensated”.
What warranties do we make about the Information?
None. We make no warranty or representation about the Information, including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable and as such, your use of the Information is at your own risk. The Information is provided as is without limitation.
What we are not.
We are not and do not act in the capacity of any of the following; as such, you should not construe our activities as involving any of the following:
An independent adviser or consultant;
A fortune teller;
An investment adviser or an entity engaging in activities that would be deemed to be providing investment advice that requires registration either at the federal or state level;
A broker-dealer or an individual acting in the capacity of a registered representative or broker;
A stock picker;
A securities trading expert;
A securities researcher or analyst;
A financial planner or one who engages in financial planning;
A provider of stock recommendations;
A provider of advice about buy, sell or hold recommendations as to specific securities; or
An agent offering or securities for sale or soliciting their purchase.
Are risks in this disclaimer the only risks investors should be aware of?
No. There are numerous risks associated with each Profiled Issuer and investors should undertake a full review of each Profiled Issuer with the assistance of their financial, legal, and tax advisers prior to purchasing the securities of any Profiled Issuer.
What conflicts of interest do we have in publishing the Information?
We are not objective or independent and have multiple conflicts of interest. The Profiled Issuers and parties hiring us have conflicts of interest.
What will happen to the shares that we hold during the Campaign?
We will sell the shares we hold while we tell investors to purchase.
Our publication of the Information involves actual and material conflicts of interest including but not limited to the following:
We receive monetary and/or securities compensation in exchange for publishing the (favorable) Information about the Profiled Issuers;
We do not publish any negative information whatsoever about the Profiled Issuers;
We may own a Profiled Issuer’s securities that we acquired from the Profiled Issuer, third parties or from our own open market purchases before, during or after the Campaign and we may sell these securities during the Campaign while publishing the (favorable) information that instructs investors to purchase. Our selling of a Profiled Issuer’s securities will likely cause investors to suffer losses;
A short time after we acquire a Profiled Issuer’s securities, we may publish the (favorable) Information about the Profiled Issuer advising others, including you, to purchase; and while doing so, we may sell the Profiled Issuer’s securities we acquired during our public dissemination of the Information causing us to profit while you suffer a loss;
Parties holding a Profiled Issuer’s securities, including those who engage our services and/or compensate us, will sell their shares of the Profiled Issuer while we are publishing the (favorable) Information.
Who is responsible if an investor relies on the Information?
The investor. We are not responsible or liable for any person’s use of the Information or any success or failure that is directly or indirectly related to such person’s use of the Information because we have specifically stated that the information is not reliable and should not be relied upon for any purpose. We are not responsible for omissions or errors in the Information, and we are not responsible for actions taken by any person who relies upon the Information.
What do we urge potential investors to do?
We urge Investors to conduct their own in-depth investigation of the Profiled Issuers with the assistance of their legal, tax and investment advisers. An investor’s review of the Information should include but not be limited to the Profiled Issuer’s financial condition, operations, management, products or services, trends in the industry and risks that may be material to the profiled Issuer’s business and other information he and his advisers deem material to an investment decision. An investor’s review should include, but not be limited to a review of available public sources and information received directly from the Profiled Issuers or from websites such as Google, OTC Markets, NASDAQ, NYSE, www.sec.gov or other available public sources.
Why is this Disclaimer being provided?
We are providing you with this disclaimer because we are publishing advertisements about penny stocks. Because we are paid to disseminate the Information to the public about securities, we are required by the securities laws including Section 10(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 thereunder, and Section 17(b) of the Securities Act of 1933, as amended (the “Securities Act”), to specifically disclose our compensation as well as other important information, This information includes that we may hold, as well as purchase and sell, the securities of a Profiled Issuer before, during and after we publish favorable Information about the Profiled Issuer. We may urge investors to purchase the securities of a Profiled Issuer while we sell our own shares.
The anti-fraud provisions of federal and state securities laws require us to inform you that we may engage in buying and selling of Profiled Issuer’s securities before, during and after the Campaigns.What are other risks that investors should be aware of?
Any investment in the Profiled Issuers involves a high degree of risk and uncertainty. The securities may be subject to extreme volume and price volatility, especially during the Campaigns. Favorable past performance of a Profiled Issuer does not guarantee future results. If you purchase the securities of the Profiled Issuers, you should be prepared to lose your entire investment. Some of the risks involved in purchasing securities of the Profiled Issuers include, but are not limited to the risks stated below.
We do not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information. We conduct no due diligence or investigation whatsoever of the Information or the Profiled Issuers and we do not receive any verification from the Profiled Issuer regarding the Information we disseminate.
If we publish any percentage gain of a Profiled Issuer from the previous day close in the Information, it is not and should not be construed as an indication that the future stock price or future operational results will reflect gains or otherwise prove to be advantageous to your investment.
The Information may contain statements asserting that a Profiled Issuer’s stock price has increased over a certain period of time which may reflect an arbitrary period of time, and is not predictive or of any analytical quality; as such, you should not rely upon the (favorable) Information in your analysis of the present or future potential of a Profiled Issuer or its securities.
The Information should not be interpreted in any way, shape, form or manner whatsoever as an indication of the Profiled Issuer’s future stock price or future financial performance.
You may encounter difficulties determining what, if any, portions of the Information are material or non-material, making it all the more imperative that you conduct your own independent investigation of the Profiled Issuer and its securities with the assistance of your legal, tax and financial advisor.
We or other stock promoters may receive free trading shares as compensation or we may acquire such shares in open market transactions before and during the Campaigns, and we may sell the shares we acquire at any time, even during the Campaigns while publishing the Favorable Information. When we sell the shares of the Profiled Issuers that we hold, the price at which investors can sell their shares will dramatically decrease and will likely cause investors to suffer trading losses.
We may sell securities of the Profiled Issuers for less than target prices set forth in the Information, and we may profit by selling our securities during the Campaigns while investors encounter losses.
When we acquire, purchase or sell the securities of the Profiled Issuers, it may (a) cause significant volatility in the Profiled Issuer’s securities; (b) cause temporary but unrealistic increases in volume and price of the Profiled Issuer’s securities; (c) if selling, cause the Profiled Issuer’s stock price to decline dramatically; and (d) permit us to make substantial profits while investors who purchase during the Campaign experience significant losses.
The securities of the Profiled Issuers are high risk, unstable, unpredictable and illiquid which may make it difficult for investors to sell their securities of the Profiled Issuers.
If we are compensated in improperly free trading securities of the Profiled Issuers, either directly or indirectly from persons who claim to be non-affiliates of such Profiled Issuer, we and the Profiled Issuer or third party could be subject to SEC Enforcement Action, including allegations of an illegal distribution in violation of Section 5(a) and 5(c) of the Securities Act.
We may hire third party service providers and stock promoters to electronically disseminate live news regarding the Profiled Issuers, yet we have no control over the content of and do not verify the information that the Profiled Issuers and/or third party service providers publish. These third party service providers are likely compensated for providing positive information about the Issuer and fail to disclose their compensation to you.
If a Profiled Issuer is an SEC reporting company, it could be delinquent (not current) in its periodic reporting obligations (i.e., in its quarterly and annual reports), or if it is an OTC Markets Pink Sheet quoted company, it may be delinquent in its Pink Sheet reporting obligations, which may result in OTC Markets posting a negative legend pertaining to the Profiled Issuer at www.otcmarkets.com, as follows: (i) “Limited Information” for companies with financial reporting problems, economic distress, or that are unwilling to file required reports with the Pink Sheets; (ii) “No Information,” which characterizes companies that are unable or unwilling to provide any disclosure to the public markets, to the SEC or the Pink Sheets; and (iii) “Caveat Emptor,” signifying buyers should be aware that there is a public interest concern associated with a company’s illegal spam campaign, questionable stock promotion, known investigation of a company’s fraudulent activity or its insiders, regulatory suspensions or disruptive corporate actions.
If the Information states that a Profiled Issuer’s securities are consistent with the future economic trends or even if your independent research indicates that, you should be aware that economic trends have their own limitations, including: (a) that economic trends or predictions may be speculative; (b) consumers, producers, investors, borrowers, lenders and government may react in unforeseen ways and be affected by behavioral biases that we are unable to predict; (c) human and social factors may outweigh future economic trends that we state may or will occur; (d) clear cut economic predictions have their limitations in that they do not account for the fundamental uncertainty in economic life, as well as ordinary life; (e) economic trends may be disrupted by sudden jumps, disruptions or other factors that are not accounted for in economic trends analysis; in other words, past or present data predicting future economic trends may become irrelevant in light of new circumstances and situations in which uncertainty becomes reality rather than predicted economic outcome; or (f) if the trend predicted involves a single result, it ignores other scenarios that may be crucial to make a decision in the event of unknown contingencies.
The Information is presented only as a brief snapshot of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities. You should consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.govwww.sec.gov, www.otcmarkets.com or other electronic media, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the OTCMarkets.com; (c) obtaining and reviewing publicly available information contained in commonly known search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.org. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and the OTC Markets and/or have negative legends and designations at otcmarkets.com.
What we were paid to advertise the Profiled Issuers.
The details of our compensation and the period of the Campaign is set forth below.
Name of Issuer & Ticker Symbol - Delic Holdings Inc. (DELCF)
Amount & Form of Compensation - $150,000.00 in cash
Who Paid for the Campaign & Position with Company if any - Delic Holdings Inc. (DELCF)
Period of Campaign - 08/15/2021 - 10/15/2021
What securities of the Profiled Issuers do we hold?
The positions we hold of the Profiled Issuer are set forth below. We plan to sell these securities during the Campaign.
. To find out more, read our